Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Corbus Pharmaceuticals Holdings (CRBP) EBIT Margin (2016 - 2021)

Corbus Pharmaceuticals Holdings has reported EBIT Margin over the past 7 years, most recently at 14257.07% for Q3 2021.

  • For Q3 2021, EBIT Margin fell 1149635.0% year-over-year to 14257.07%; the TTM value through Jun 2022 reached 45961.32%, down 4363525.0%, while the annual FY2021 figure was 6350.09%, 389388.0% down from the prior year.
  • EBIT Margin for Q3 2021 was 14257.07% at Corbus Pharmaceuticals Holdings, down from 12230.01% in the prior quarter.
  • Over five years, EBIT Margin peaked at 95.17% in Q4 2019 and troughed at 14257.07% in Q3 2021.
  • A 5-year average of 3693.1% and a median of 1429.2% in 2018 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: surged 884691bps in 2019 and later plummeted -1332495bps in 2020.
  • Year by year, EBIT Margin stood at 873.63% in 2017, then plummeted by -902bps to 8751.74% in 2018, then soared by 101bps to 95.17% in 2019, then plummeted by -1371bps to 1209.33% in 2020, then plummeted by -1079bps to 14257.07% in 2021.
  • Business Quant data shows EBIT Margin for CRBP at 14257.07% in Q3 2021, 12230.01% in Q2 2021, and 2379.38% in Q1 2021.